The first-line treatments for metastatic PC are androgen-deprivation therapy (ADT) and AR-targeting therapy, but secondary resistance coupled with enhanced metastatic potential is a crucial challenge in these treatments [12]. This evidence concerns the gene AR and pachyonychia congenita.